Amphastar Pharmaceuticals reported a strong first quarter in 2020, with net revenues of $84.7 million and GAAP net income of $3.9 million, driven by strong sales of Primatene® Mist and hospital products.
Net revenues reached $84.7 million for the first quarter.
GAAP net income was $3.9 million, or $0.08 per share, for the first quarter.
Adjusted non-GAAP net income amounted to $8.4 million, or $0.17 per share, for the first quarter.
Increased sales of Primatene® Mist were driven by successful marketing and pantry loading due to COVID-19.
The financial results for the three months ended March 31, 2020, were not significantly impacted by the COVID-19 pandemic, except for the increased sales of Primatene® Mist and some hospital products. It is not possible at this time to estimate the impact that COVID-19 could have on our business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance